A phase I study of tipifarnib in combination with imatinib mesylate (IM) for patients (Pts) with chronic myeloid leukemia (CML) in chronic phase (CP) who failed IM therapy.

被引：0
|
作者：
Cortes, J
Garcia-Manero, G
O'Brien, S
Hernandez, I
Rackoff, W
Faderl, S
Thomas, D
Ferrajoli, A
Talpaz, M
Kantarjian, H
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Johnson & Johnson Pharmaceut Res & Dev, LLC, Titusville, NJ USA
来源：
BLOOD | 2004年 / 104卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1011
引用
收藏
页码：289A / 289A
页数：1
相关论文
共 50 条
  • [1] Conception and pregnancy in patients (pts) with chronic myeloid leukemia (CML) receiving therapy with imatinib mesylate (IM).
    Ault, P
    Kantarjian, H
    O'Brien, S
    Koller, C
    Faderl, S
    Freireich, EJ
    Rios, MB
    Cortes, J
    BLOOD, 2005, 106 (11) : 321A - 321A
  • [2] Phase 2 study of dasatinib in Chinese patients with chronic myeloid leukemia (CML) in chronic phase (CP) or advanced phase who are resistant to or intolerant of imatinib (IM)
    Wang, Jianxiang
    Huang, Xiaojun
    Hu, Jianda
    Li, Jianyong
    Jin, Jie
    Meng, Fanyi
    Shen, Zhixiang
    Liu, Ting
    Wu, Depei
    Wang, Jianmin
    LEUKEMIA & LYMPHOMA, 2013, 54 : 3 - +
  • [3] A phase III study exploring various doses of imatinib (IM) or IM in combination for newly diagnosed chronic phase (CP) chronic myeloid leukemia (CML) patients (pts): Results of an interim analysis of the SPIRIT trial of French CML group
    Nicolini, F. E.
    Mahon, F. X.
    Guilhot, J.
    Buzyn, A.
    Tulliez, M.
    Berthou, C.
    Christian, B.
    Guyotat, D.
    Preudhomme, C.
    Guilhot, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [4] A phase II study of intravenous (IV) homoharringtonine (HUT) and imatinib (IM) in patients (pts) with chronic myeloid leukemia (CML).
    Quintas-Cardama, Alfonso
    Kantarjian, Hagop M.
    Wierda, William
    Ferrajoli, Alessandra
    Chen, Rong
    Ravandi, Farhad
    Plunkett, William
    Cortes, Jorge
    BLOOD, 2006, 108 (11) : 616A - 617A
  • [5] Safety and efficacy of bosutinib (SKI-606) in patients (pts) with chronic phase (CP) chronic myeloid leukemia (CML) following resistance or intolerance to imatinib (IM)
    Cortes, J. E.
    Kantarjian, H.
    Bruemmendorf, T.
    Khoury, H. J.
    Kim, D.
    Turkina, A.
    Volkert, A.
    Wang, J.
    Arkin, S.
    Gambacorti-Passerini, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [6] High-dose imatinib mesylate treatment in patients (pts) with previously untreated early chronic phase (CP) chronic myeloid leukemia (CML).
    Cortes, J
    Talpaz, M
    O'Brien, S
    Giles, F
    Rios, MB
    Levtak, L
    Kantarjian, H
    BLOOD, 2004, 104 (11) : 285A - 286A
  • [7] Phase I study of a imatinib and lonafarnib (SCH66336) in patients (pts) with chronic myeloid leukemia (CML) refractory to imatinib mesylate.
    Cortes, J
    O'Brien, S
    Ferrajoli, A
    Daley, GQ
    Pate, O
    Verstovsek, S
    Faderl, S
    Zhu, YL
    Sugrue, M
    Statkevich, P
    Talpaz, M
    Kantarjian, H
    BLOOD, 2003, 102 (11) : 909A - 909A
  • [8] Early molecular response in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) treated with dasatinib (DAS) or imatinib (IM) from DASISION.
    Shah, Neil P.
    Saglio, Giuseppe
    Hochhaus, Andreas
    Bilmes, Robyn
    Li, Li
    Cortes, Jorge E.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [9] Secondary leukemia after imatinib mesylate (IM) therapy for chronic myelogenous leukemia (CML).
    Kovitz, CA
    Kantarjian, HM
    Garcia-Manero, G
    Abruzzo, LV
    Cortes, JE
    BLOOD, 2005, 106 (11) : 295B - 295B
  • [10] Chromosomal abnormalities in Philadelphia chromosome (Ph)-negative metaphases appearing during imatinib mesylate (IM) therapy in patients (pts) with newly diagnosed chronic myeloid leukemia (CML) in chronic phase.
    Jabbour, E
    Kantarjian, H
    O'Brien, S
    Verstovsek, S
    Garcia-Manero, G
    Rioss, MB
    Cortes, J
    BLOOD, 2005, 106 (11) : 317A - 318A
12345